Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria? by Ogutu, Bernhards et al.
OPINION Open Access
Treatment of asymptomatic carriers with
artemether-lumefantrine: an opportunity to
reduce the burden of malaria?
Bernhards Ogutu
1,2*, Alfred B Tiono
3, Michael Makanga
4, Zulfiqarali Premji
5, Adama Dodji Gbadoé
6, David Ubben
7,
Anne Claire Marrast
8, Oumar Gaye
9
Abstract
Background: Increased investment and commitment to malaria prevention and treatment strategies across Africa
has produced impressive reductions in the incidence of this disease. Nevertheless, it is clear that further
interventions will be necessary to meet the international target of a reversal in the incidence of malaria by 2015.
This article discusses the prospective role of an innovative malaria control strategy - the community-based
treatment of asymptomatic carriers of Plasmodium falciparum, with artemisinin-based combination therapy (ACT).
The potential of this intervention was considered by key scientists in the field at an Advisory Board meeting held
in Basel, in April 2009. This article summarizes the discussions that took place among the participants.
Presentation of the hypothesis: Asymptomatic carriers do not seek treatment for their infection and, therefore,
constitute a reservoir of parasites and thus a real public-health risk. The systematic identification and treatment of
individuals with asymptomatic P. falciparum as part of a surveillance intervention strategy should reduce the
parasite reservoir, and if this pool is greatly reduced, it will impact disease transmission.
Testing the hypothesis: This article considers the populations that could benefit from such a strategy and
examines the ethical issues associated with the treatment of apparently healthy individuals, who represent a
neglected public health risk. The potential for the treatment of asymptomatic carriers to impair the development
of protective immunity, resulting in a ‘rebound’ and age escalation of malaria incidence, is also discussed.
For policymakers to consider the treatment of asymptomatic carriers with ACT as a new tool in their malaria con-
trol programmes, it will be important to demonstrate that such a strategy can produce significant benefits, without
having a negative impact on the efficacy of ACT and the health of the target population.
Implications of the hypothesis: The treatment of asymptomatic carriers with ACT is an innovative and essential
tool for breaking the cycle of infection in some transmission settings. Safe and effective medicines can save the
lives of children, but the reprieve is only temporary so long as the mosquitoes can become re-infected from the
asymptomatic carriers. With improvements in rapid diagnostic tests that allow easier identification of asymptomatic
carriers, the elimination of the pool of parasites is within reach.
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The last two decades have seen an increasing level of
international attention directed towards malaria. In
2000, the Millennium Development Goals called for a
reversal in the incidence of this disease by 2015. Follow-
ing the publication of this ambitious goal, an increased
commitment to a number of treatment and prevention
strategies has produced some impressive results. In
Rwanda, Ethiopia, and Zanzibar, the mass distribution
of insecticide-treated bed nets (ITNs), coupled with
increasing use of long-lasting ITNs and nationwide
adoption of artemisinin-based combination therapy
(ACT), resulted in substantial declines in malaria-related
deaths [1,2]. Similarly, interventions to increase the cov-
erage of ITNs in The Gambia and to improve vector
control through a programme of indoor residual spray-
ing (IRS) in South Africa have both produced marked
reductions in confirmed malaria cases [3,4]. Despite
these considerable successes, it is clear that additional
complementary interventions are still required to further
reduce the disease burden in areas that have already
achieved low transmission. In this situation, the use of
surveillance for systematic treatment of asymptomatic
cases becomes an intervention of choice.
I nt h ec u r r e n tc l i m a t eo fc o n s i d e r a b l ei n t e r n a t i o n a l
attention and funding for the control of malaria, it is
important to strive for the implementation of integrated,
novel interventions. If substantial headway is not made
in controlling malaria in the coming years, it is possible
that the attention of donors and funding agencies may
drift to other diseases. It is, therefore, critical to seize
the current opportunity to implement pioneering, co-
ordinated strategies that have a high likelihood of pro-
ducing an impact. This article proposes that the treat-
ment of asymptomatic carriers represents an
opportunity to reduce the burden of malaria.
The prevalence of asymptomatic carriage of Plasmodium
falciparum
In malaria-endemic countries, a large proportion of P.
falciparum infections are asymptomatic or sub-clinical.
Microscopy-detected levels of asymptomatic carriage as
high as 39% have been reported (Table 1) [5-9]. Invari-
ably, this hidden pool of parasites is essential for main-
taining the cycle of infection. Asymptomatic carriers do
not seek treatment for their infection and, therefore,
constitute a reservoir of parasites available for
transmission by mosquitoes. Even in areas of highly sea-
sonal malaria transmission, where the incidence of clini-
cal malaria is significantly lower during the dry season,
s t u d i e sh a v es h o w nt h a tac o n s i d e r a b l ep r o p o r t i o no f
the population remain positive for parasitaemia through-
out the year [6,8,10,11]. Indeed, these reports might
underestimate the level of asymptomatic carriage during
the dry season, as gametocytes have been detected in
prolonged sub-microscopic infections [12,13]. Interest-
ingly, the prevalence of asymptomatic carriage has been
reported to be greatest in adolescents and children; in a
study in The Gambia, the prevalence of asexual parasi-
taemia (61%) was highest in individuals aged 5-15 years
[8].
Presentation of the hypothesis
Reducing the parasite reservoir
On the basis of these measurements, it is clear that the
systematic identification and treatment of asymptomatic
carriers, as part of a surveillance strategy towards
malaria elimination, could reduce the pool of parasites
available for the infection of mosquitoes. Therefore, if a
significant reduction of the malaria parasite pool could
be obtained through treatment of asymptomatic carriers,
over a period of time, a reduction in disease transmis-
sion could be obtained across the entire endemic popu-
lation, even in areas of high transmission.
The transmission of P. falciparum parasites from
humans to mosquitoes requires the presence of infec-
tious gametocytes in the human peripheral blood. Con-
sequently, for the treatment of asymptomatic carriers to
result in a reduction of disease transmission, the therapy
used must have some effectiveness against the transmis-
sible sexual stage of the parasite. In comparison with
non-artemisinin regimens, treatment with artemisinin
derivatives has been shown to result in lower gameto-
cyte carriage rates [14,15], and reduced infectivity of
treated individuals [16].
Among the ACT currently on the market, artemether-
lumefantrine is a good candidate for the treatment of
asymptomatic carriers for a number of important rea-
sons. The efficacy and safety of this ACT have been
clearly demonstrated in a clinical development pro-
gramme spanning 14 years and enrolling approximately
5,000 patients. In trials conducted in different malaria-
endemic regions, artemether-lumefantrine has
Table 1 Prevalence of asymptomatic carriage of P. falciparum in sub-Saharan Africa
Gabon [7] Kenya [9] Mozambique [5] Senegal [6] The Gambia [8]
Population studied Adult males 18-51
years old
Children 5-17
years old
Children under 10
years old
Children 2-10
years old
Individuals >6
months old
Prevalence of asymptomatic carriage
(method of detection)
12% (microscopy)
27% (RDT)
52% (PCR)
12.6%
(microscopy)
33.3% (RDT)
39.2% (microscopy) 35%
(microscopy)
32% (microscopy)
Ogutu et al. Malaria Journal 2010, 9:30
http://www.malariajournal.com/content/9/1/30
Page 2 of 7consistently achieved 28-day PCR-corrected cure rates
of >95% [17-21], and has shown a good safety and toler-
ability profile in infants, children and adults [17-22].
Treatment of confirmed carriers not preventive treatment
It is important that any discussion of the treatment of
asymptomatic carriers clearly differentiates this strategy
from mass drug administration (MDA), as employed for
filariasis, or intermittent preventive treatment (IPT) of
malaria. MDA involves blanket treatment of the entire
endemic population. During IPT, members of an at-risk
population are given a full therapeutic dose of treatment
at set times, without an attempt to determine infection
status. By contrast, a strategy of treating asymptomatic
carriers would involve confirmation of parasitaemia
using Rapid Diagnostic Tests (RDTs) before treatment.
The current deployment of RDTs across sub-Saharan
Africa provides a feasible platform for the diagnosis and
treatment of the majority of asymptomatic carriers. In
stark contrast to policies of MDA, which caused fears
over resistance development[23], only individuals with
confirmed parasitaemia would receive treatment and
this would be a full therapeutic course of treatment,
minimizing unnecessary drug use and limiting the risk
of any parasite resistance developing to the ACT.
RDT false negativity due to very low parasitaemia or
parasite genetic polymorphisms is a possible limitation
of RDT screening, as is the difficulty of reaching all
members of a community. The most sensitive method
for detecting parasitaemia is PCR; however, this techni-
que requires specific equipment that is largely unavail-
able in rural communities. Identification of
asymptomatic carriers through a programme of RDT
testing and re-testing is a pragmatic approach, which
should reduce the parasite reservoir to a level sufficient
to interrupt disease transmission. With repeated surveys
and active asymptomatic case detection at health facil-
ities, sufficient levels of treatment could be obtained. As
more robust and user-friendly diagnostics become avail-
able they could be integrated into the surveillance
strategy.
Preserving the efficacy of ACT
One of the challenges likely to be raised to the treat-
ment of asymptomatic carriers is the potential for such
a strategy to engender the development of resistance to
ACT. A recent study indicates that the probability of
resistance selection in asymptomatic infections is lower
than with symptomatic infections. The requirement for
a resistant parasite to derive from a new antigenic var-
iant, and the much lower total number of parasites pre-
sent in an asymptomatic infection lower the probability
of a de-novo resistant parasite emerging and reaching a
transmissible density [24].
Furthermore, the relatively short half-life of lumefan-
trine makes artemether-lumefantrine an ideal choice for
use in this strategy. At approximately 3-6 days, the half-
life of lumefantrine is markedly shorter than those of
other artemisinin companion drugs, such as mefloquine
(2-3 weeks), chloroquine (8-58 days) and piperaquine
(2-3 weeks) [25-27]. Resistance to anti-malarial drugs is
most likely to occur when a large population of parasites
are exposed to sub-therapeutic concentrations of a sin-
gle anti-malarial. Rapidly eliminated drugs, such as the
artemisinin derivatives, cannot protect the partner drug
once blood concentrations have fallen below therapeutic
levels. Consequently, those ACT that contain partner
drugs with a long half-life should, theoretically, be at a
greater risk for the development of resistance. Notably,
a study that examined the pharmacokinetic determi-
nants of resistance selection showed lumefantrine to
h a v eac o n s i d e r a b l ys h o r t e r‘window of selection’ than
mefloquine and chloroquine [28].
The use of a surveillance strategy for the treatment of
asymptomatic carriers, once a state of low malaria trans-
mission is achieved, will ultimately result in a reduction
in the disease burden. The proportion of the population
exposed to anti-malarials over time will, therefore, be
reduced, limiting the possibility of a drug pressure effect
that could drive the emergence of resistance to anti-
malarials.
Modelling of parasite dynamics with respect to drug
resistance would be an important part of any pilot
implementation of this strategy, and the effects of other
malaria control interventions, both current and future,
would need to be considered appropriately.
Testing the hypothesis
Defining the population
In sub-Saharan Africa, many of the preventive interven-
tions, such as provision of ITNs and IPT, have focused
on those populations most vulnerable to malaria mortal-
ity: children under five years of age and pregnant
women [29]. For these particular interventions, an
approach that targets the high-risk groups is plausible
and appropriate, given the limited resources available
and with increased survival rather than disease elimina-
tion as the main outcome. The ultimate aim of surveil-
lance and treatment of asymptomatic carriers, however,
is eradication of disease transmission, which requires
screening of all members of a population. The primary
intention of the strategy is to dramatically reduce the
pool of parasites available for infection of mosquitoes.
To break the cycle of transmission, high parasite clear-
ance rates would need to be attained across all members
of a community, not only the vulnerable populations.
Although the treatment of asymptomatic carriers
would have benefits in all transmission settings, it is
likely that the initial proof of concept would be easiest
to achieve in areas of highly seasonal transmission. In
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heavily dependent on asymptomatic carriage of parasites
during the dry season. Consequently, treatment of
asymptomatic carriers before the start of the rainy sea-
son and dry season could dramatically reduce the source
of P. falciparum infection for newly emerging mosqui-
toes. In high malaria transmission areas such as Rwanda,
South Africa and Zanzibar, which have already achieved
a marked reduction in the disease burden following
scale-up of ITNs, IRS, ACT and IPT, this could be an
appropriate strategy to further reduce the disease bur-
den and move towards parasite elimination.
Measuring the benefits
As adolescents and adults experience far fewer episodes
of clinical malaria, the primary benefits of this strategy
w o u l dn e e dt ob em e a s u r e di nt h em o s tv u l n e r a b l e
members of the population: children less than five years
of age. With a reduction in disease transmission, chil-
dren under five years of age would experience fewer
cases of clinical malaria with improved survival and
quality of life.
To convince policymakers of the potential benefits of
this strategy, any pilot study would need to examine
endpoints that are likely to be of interest to this audi-
ence. Consequently, while the immediate result of treat-
ing asymptomatic carriers will be to reduce the
prevalence of asymptomatic carriage, the impact of the
strategy on the incidence of clinical malaria in children
aged less than five years will be the far more compelling
measurement for policymakers.
Cost and affordability will be key factors for policy-
makers. In this regard, it is likely that the cost of testing
individuals and treating asymptomatic carriers would be
more than offset by the reduced number of malaria-
related hospital admissions and patient visits, and by the
man hours gained. In 2002, Muheki et al calculated that
the average cost of each malaria-related hospital admis-
sion in the KwaZulu Natal province of South Africa was
(US$) 173.5 and an outpatient visit was $7.52 [30]. With
a drop in malaria incidence, these significant healthcare
costs could be reduced. However, there are costs that
would need to be taken into consideration such as those
associated with community education to encourage par-
ticipation and adherence to treatment, and enhancement
of healthcare systems to facilitate implementation of the
strategy. All in all, the anticipated gains should outweigh
the costs, with the strategy resulting in a reduction in
disease burden and improved healthcare systems that
have an emphasis on disease prevention. Recent work
has demonstrated the pervasive effect of malaria on a
country’s socioeconomic situation [31]. Consequently, a
credible case could be made for evaluating the impact of
malaria control interventions from a macro-socioeco-
nomic standpoint. Clearly a full health-economic
analysis would be an essential part of the implementa-
tion of any pilot study that examines the potential of
this intervention.
The challenges associated with the treatment of
asymptomatic carriers
One of the challenges this control strategy would need
to address is the need to treat ‘apparently’ healthy indi-
viduals. Indeed, convincing asymptomatic individuals to
comply with treatment could prove difficult, as the
usual pay-off of symptom resolution with treatment
would not be present. It is important to emphasize,
however, that while asymptomatic carriers do not pre-
sent with the symptoms of clinical malaria, they still
carry a burden from the disease. Anaemia related to
malaria has been recorded in asymptomatic individuals
in a number of studies [32-34], and malaria preventive
measures have been shown to reduce the prevalence of
anaemia in school-aged children [34,35]. Anaemia has
been related to reduced work capacity [36], poor preg-
nancy outcomes [37], and reduced cognitive function
[38]. It is, therefore, anticipated that individual carriers
would derive benefit from clearance of their
parasitaemia.
With the use of appropriate healthcare educational
tools to convey the population and individual benefits,
and in the knowledge that the uptake of previous mass
vaccination programmes by healthy individuals has pro-
ven successful - such as the campaign to educate the
population regarding the elimination of polio, sufficient
uptake of treatment by asymptomatic individuals should
be possible. Community involvement in the programme
would be vital to encourage high levels of participation.
Notably, excellent adherence to the artemether-lumefan-
trine treatment regimen during clinical malaria has been
reported [39,40].
A further potential barrier would be convincing pub-
lic-health officials of the favourable risk-to-benefit pro-
file of the strategy. In contrast to the treatment of
patients with clinical malaria, the benefits conferred by
the treatment of asymptomatic carriers would largely be
at the population rather than individual level. Therefore,
policymakers would need to be convinced that the
population-level benefits are sufficiently large to justify
the treatment of apparently healthy individuals with
anti-malarials. In this regard, it would be extremely
important to use an ACT, such as artemether-lumefan-
trine, for which a good safety and tolerability profile has
been clearly established.
Another concern that would need to be addressed is
the potential for such a strategy to impair the develop-
ment of protective immunity. It is known that children
living in malaria-endemic areas gradually acquire immu-
nity to the disease, and their risk for clinical malaria is
markedly reduced by adolescence. If the development of
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this might result in a ‘rebound’ of malaria incidence. On
consideration, however, it seems unlikely that the strat-
egy would result in a significant rebound effect. Firstly,
the strategy does not prevent the exposure of individuals
to parasites; indeed, individuals only receive treatment
once it has been confirmed that they have parasitaemia.
Secondly, similar concerns were raised with regard to
the widespread implementation of IPT strategies and
use of ITNs for infants and small children, but subse-
quent studies have indicated that the rebound effect was
not as significant as hypothesized [41-48]. Studies of
ITN-type strategies in Burkina Faso, Ghana and Kenya
found no evidence to suggest a shift in mortality from
younger to older children [41-43]. Similarly, several stu-
dies looking for evidence of a rebound effect following
IPT have failed to find an increase in the incidence of
malaria in the subsequent year [44-48].
While this strategy may alter the profile of malaria
immunity, its use is proposed in the context of malaria
eradication. In such a setting, the fear of waning malaria
immunity and subsequent disease rebound must be
balanced against the huge quality of life benefits and
opportunities that would be obtained with eradication of
the disease. Many individuals in malaria-endemic
regions do not reach their full potential, owing to the
lifelong consequences of early malaria infections. Studies
have shown that IPT strategies, that reduced parasitae-
mia in children, resulted in better school performance
and quality of life [34,49]. These findings cast doubt on
the value of retaining parasites in order to maintain
immunity at the expense of individuals attaining their
full life potential. A significant reduction in disease pre-
valence should also lead to considerable socioeconomic
as well as health-related benefits including improved
healthcare systems.
The fundamental aim of the malaria eradication
agenda is to eliminate the parasite, which will ultimately
result in a loss of immunity for the entire population,
since malaria infection does not confer lifelong immu-
nity. For individuals moving to areas still endemic for
disease, other treatment and preventive strategies such
as prophylaxis would still be available.
Fears over the adverse effects that could result from
failure of a malaria elimination programme should not
result in the surrender of ambition. The knowledge of
such possibilities allows active management of these
challenges, and should not prevent the development and
deployment of new strategies that are likely to accelerate
achievement of the ultimate aim - malaria elimination.
Although the programme for malaria eradication failed
in Africa previously, it was successful in other areas, and
thus with lessons learnt, greater global commitment,
and the availability of a greater number of tools, the
community must strive for success.
Implications of the hypothesis
In light of the recent successes associated with the
introduction of ITNs, IRS and ACT, and the increased
international attention being given to malaria control
and prevention it is time to explore new disease-control
strategies that can build on the achievements of the past
20 years. The treatment of asymptomatic carriers as
part of a surveillance strategy has the potential to make
a very significant contribution to the multifaceted
approaches being implemented by malaria control pro-
grammes across Africa. Accordingly, suitable pilot stu-
dies designed to obtain evidence of the benefits of this
strategy should now be a priority. These pilot studies
are likely to be large, expensive and complex in their
design, but are essential to develop this extremely pro-
mising concept into a scientifically well-formulated
strategy.
As the malaria community begins to seriously consider
malaria elimination in certain epidemiological settings,
there is a clear need to broaden the research agenda
and develop new control interventions [50,51]. The
treatment of asymptomatic carriers is one such interven-
tion that would work in conjunction with existing
approaches such as prompt and effective case manage-
ment, IPT and vector control, as well as with future
strategies such as a vaccine against malaria.
In conclusion, a co-ordinated surveillance strategy to
identify and treat both symptomatic and asymptomatic
carriers of P. falciparum has great potential to reduce
disease transmission towards elimination. Although such
a strategy would present a number of operational chal-
lenges, if compelling evidence of the benefits of this
intervention could be produced, solutions to the imple-
mentation barriers would be found, as demonstrated by
previous vaccination campaigns.
Effective anti-malarials save lives; however, without a
significant reduction in disease transmission, these indi-
viduals quickly become reinfected and the cycle con-
tinues with the potential for the development of
resistance and the loss of lives. With improvements in
diagnostic tools, such as RDTs, which allow for easier
and more accurate identification of asymptomatic car-
riers, it is possible that the elimination of the pool of
parasites is within reach.
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